Hypoxia-inducible factors in erythropoiesis, iron ...Hypoxia-inducible factors in erythropoiesis,...
Transcript of Hypoxia-inducible factors in erythropoiesis, iron ...Hypoxia-inducible factors in erythropoiesis,...
https://www.haaselab.org
Volker H. Haase M.D.Krick-Brooks Chair in Nephrology
Professor of MedicineVanderbilt University
Hypoxia-inducible factors in erythropoiesis, iron homeostasis and beyond
@HIFpathway
KDIGO
Outline: HIF in erythropoiesis
u overview
u EPO synthesis in kidney and liver
u iron metabolism
u renal anemia
u HIF beyond erythropoiesis
KDIGO
Physiologic Responses to Hypoxia:This what happens when you go to high altitude
Andrew M. Luks J Appl Physiol 2015;118:509-519
©2015 by American Physiological Society
KDIGO
EPO and Hgb responses at high altitude
Faura et al., Blood, 1969
Abbrecht and Littel, J. Appl. Physiol., 1972
KDIGO
HIF controls the Hypoxic Induction of EPO
Haase, VH
KDIGO
HIF regulates multiple processes:biological target complexity
HIF
Vasculogenesis/AngiogenesisHeme oxygenase-2NOS-2, PAI - IVEGF, VEGF-R (FLT-1)
Iron metabolism /ErythropoiesisCeruloplasminEPO (HIF-2 > HIF-1)TransferrinTransferrin R
Metabolism: Glycolysis (HIF-1)Fat metabolism (HIF-2)Adenylate kinase-3Carbonic anhydrase-9Glut-1 and -3Glycolytic enzymes(Hexokinase, LDH,PGK, etc.)Leptin
Proliferation/Cell survivalCyclin G2, EPO, Heme oxygenase 1IGF-2, IGFBP1, -2, -3NOS-2, NIP-3, p21TGF-b3, VEGF, WT1Indirect: c-Myc
HYPOXIAvia
ECM production/Cell migrationCxCR4, c-met, CTGF, PAI-1,Procollagen prolyl hydroxylase-a1
Epithelial Barrier FunctionITF, MDR-1, CD73
Transcription factorsEts-1, DEC-1/Stra13
Haase, VH
KDIGO
Regulation of HIF-α stability: molecular complexity
Angiotensin II
Non-hypoxic stimuli:Interleukin1, TNF-a, Growth factors
HIF: hypoxia-inducible factor Haase, VH, AJP Renal 2006
KDIGO
• Wang, G.L. and Semenza, G.L. (1995). Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230-1237.
• Wang, G.L., Jiang, B.-H., Rue, E.A., and Semenza, G. L. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA. 92, 5510-5514.
• Forsythe, J.A., Jiang, B.-H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D., and Semenza, G.L. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604-4613.
• Maxwell, P.H., Pugh, C.W., and Ratcliffe, P.J. (1993). Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc. Natl. Acad. Sci. USA. 90, 2423-2427.
• Maxwell, P.H. et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399, 271-275.
• Jaakkola, P. et al. (2001). Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292, 468-472
• Epstein, A.C.R. et al.. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107, 43-54.
• Iliopoulos, O., Levy, A.P., Jiang, C., Kaelin, W.G., Jr., and Goldberg, M.A. (1996). Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA. 93, 10595-10599.
• Ohh, M., Park, C.W., Ivan, M., Hoffman, M.A., Kim, T.-Y., Huang, L.E., Chau, V., Pavletich, N., and Kaelin, W.G., Jr. (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2, 423-427.
• Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J.M., Lane, W.S., and Kaelin, W.G., Jr. (2001). HIF targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 292, 464-468
Discovery of HIF-oxygen sensing
Gregg L. SemenzaJohns Hopkins
Sir Peter J. RatcliffeOxford
William G. Kaelin, Jr.Harvard
KDIGO
2OG-dependent dioxygenases:pharmacologic target complexity
Loenarz and Schofield, Nature Chemical Biology, 2008PHD1, PHD2, PHD3FIH
KDIGO
The HIF-EPO axis
in kidney and liver
KDIGO
GATA-2/3 (5’-TGATAA-3’)
HIF-2 dependent regulation of EPO
EPO: erythropoietin; HIF: hypoxia-inducible factor.
KDIGO
EPO-producing cells in human kidneys
Kobayashi H, et al. J Clin Invest. 2016;126(5):1926-1938.
KDIGO
KDIGO
Hct 15
cortex
IM
IS
OS
Hct 26Hct 45
HIF-2 regulates the size of the REPC pool
Kobayashi H, et al. J Clin Invest. 2016;126(5):1926-1938.
KDIGO
Distinct interstitial cell populations regulate renal EPO production: cellular complexity
EPO: erythropoietin; PHD: prolyl-4-hydroxylase domain; REPC: renal EPO-producing cell.Kobayashi H, et al. J Clin Invest. 2016;126(5):1926-1938.
KDIGO
The liver as EPO source:role of individual PHDs
EPO: erythropoietin; PHD: prolyl-4-hydroxylase domain.Tojo Y, et al. Mol Cell Biol. 2015;35(15):2658-2672.
Cont
rol
P13-
L-KO
P23-
L-KO
P123
-L-K
O
P12-
L-KO
KDIGO
HIF and
iron metabolism
KDIGO
HIF in iron metabolism
Koury MJ, Haase VH. Nat Rev Nephrol. 2015;11(7): 394-410.
KDIGO
HIF-2 iron feedback via IRP
KDIGO
u the hypoxic induction of EPO in the kidney and liver is HIF-2-dependent
u inactivation of PHD2 alone is sufficient to stimulate the production of renal EPO
u there are at least two distinct populations of EPO-producing cells in the kidney that differ in their regulation of HIF-2 activity and EPO production
u inactivation of at least 2 PHD enzymes in the liver is required to stimulate erythropoiesis
u HIF coordinates erythropoiesis with iron metabolismu intracellular iron regulates HIF oxygen sensing
Key Points
EPO: erythropoietin; HIF: hypoxia-inducible factor; PHD: prolyl-4-hydroxylase domain.
KDIGO
HIF-PHD Inhibitors for renal anemia therapy: overview of compounds and mechanism
KDIGO
Pathogenesis of Renal Anemia
EPO: erythropoietin.Koury MJ, Haase VH. Nat Rev Nephrol. 2015;11(7):394-410.
KDIGO
HIF-PHDs (PHD1, PHD2, PHD3)
R +
R = HIF-α
HIF-PHD as pharmacologic target
HAASE, VH
KDIGO
HIF-PHIs chemical structures
KDIGO
Sanghani and Haase, ACKD, 2019
Pharmacologic profiles of HIF-PHIs
Others: Enarodustat (JTZ-951, Japan Tabacco), Desidustat (Zyann1, Cadila Healthcare/Zydus Cadila),TP0463518 (Taisho Pharmaceutical)
KDIGO
HIF-PHIs: mechanisms in renal anemia
KDIGO
Renal EPO-producing cells in CKD
CKD: chronic kidney disease; EPO: erythropoietin; REPC: renal EPO-producing cell.Koury MJ, Haase VH. Nat Rev Nephrol. 2015;11(7):394-410.
KDIGO
HIF-Prolyl Hydroxylase Inhibition:potential adverse effects
q VEGF ?q Metabolic effects (glucose, cholesterol, fat
metabolism, uric acid, FGF 23) ?q Pulmonary artery pressure ?q Systemic arterial blood pressure ?q Effects on kidney disease progression ?q Liver toxicity ?q Pro-oncogenic potential ?
HAASE, V.H..
KDIGO
HIF activation:potential applications in renal injury
KDIGO
Preclinical studies in AKI – evidence for renoprotection
KDIGO
Potential mechanisms of HIF-dependent
“Ischemic preconditioning”
Kapitsinou and Haase., AJP Renal, 2015
KDIGO
Key PointsØ there is strong preclinical evidence for HIF-induced
protection from acute ischemic injury warranting further investigation in patients
Ø HIF protects from renal ischemia-reperfusion injury and transition to CKD
Ø are currently used dosing regimen sufficient to afford cytoprotection (Dapro trial in PVD failed) ?
Ø the effects of HIF activation on chronic kidney injury are controversial. Preclinical studies indicate strong cell type and context dependence
KDIGO
HIF oxygen sensingcardiovascular disease
KDIGO
Cardiovascular risk in CKD: is HIF-PHI therapy beneficial ?
Gansevoort RT et al., Lancet, 2013
KDIGO
Altitude reduces all-cause mortality in incident dialysis
Winkelmayer et al., JAMA, 2009
KDIGO
HIF activation in CVD – importance of timing and duration
Minamashima et al., Blood 2008
Tanaka and Eckardt, Seminars in Nephrology, 2018
KDIGO
Key points
Ø HIF activation has the potential to reduce cardiovascular morbidity and mortality in CKD patients
Ø HIF-PHIs may have anti-inflammatory effects
Ø several cardiovascular safety concerns have not been addressed yet in long-term studies
Ø additional clinical studies are needed
Ø acute effects may be protective – timing is critical
Ø chronic HIF activation results in organ dysfunction
KDIGO